Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 0 | 886 | 2,329 | 18,739 | 0 |
| Gross Profit | N/A | 886 | 2,329 | 18,739 | N/A |
| Operating Expenses | 208,566 | 243,189 | 87,110 | 84,388 | 81,481 |
| Operating Income | -208,566 | -242,303 | -84,781 | -65,649 | -81,481 |
| Other Income | 599 | -96,513 | 830 | -11 | 588 |
| Pre-tax Income | -207,967 | -338,816 | -83,951 | -65,660 | -80,893 |
| Income Tax | 51 | -26 | -136 | 141 | N/A |
| Net Income Continuous | -208,018 | -338,790 | -83,815 | -65,801 | -80,893 |
| Net Income | $-208,018 | $-338,790 | $-83,815 | $-65,801 | $-80,893 |
| EPS Basic Total Ops | -4.42 | -49.12 | -24.86 | -25.02 | -38.00 |
| EPS Basic Continuous Ops | -4.42 | -49.12 | -24.86 | -25.02 | -37.89 |
| EPS Diluted Total Ops | -4.42 | -49.12 | -24.86 | -25.02 | -38.00 |
| EPS Diluted Continuous Ops | -4.42 | -49.12 | -24.86 | -25.02 | -37.89 |
| EPS Diluted Before Non-Recurring Items | -3.18 | -29.98 | -24.75 | -25.00 | -38.00 |
| EBITDA(a) | $-219,970 | $-243,657 | $-83,144 | $-63,100 | $-80,412 |